Berlin – A Team led by partner Martin Schaper provided comprehensive legal and tax advice to a consortium of investors led by INKEF Capital on the investment in the Series B financing round of Hanover-based Cardior Pharmaceuticals. The round has a volume of € 64 million. In addition to lead investor INKEF, new investors Fund+, Sunstone, Hadean Ventures and Coparion participated in the round. In addition, existing investors such as LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds also participated in the financing round. In connection with the financing, representatives from INKEF Capital, Fund+ and Sunstone will join the company’s advisory board. Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program and the expansion of the company’s earlier-stage pipeline.
INKEF Capital is an Amsterdam-based venture capital firm backing promising early-stage companies in Europe with a portfolio of more than 45 companies in the healthcare and technology sectors.
Download PDF
Team:
Dr. Martin Schaper (Lead), Partner
Dr. Malte Bergmann, Partner
Dr. Martyna Sabat, Senior Associate
Dr. Ansgar Frank, Associated Partner
Ann-Kristin Lochmann, Senior Associate
Pia Meven, Associate
Jonas Huth, Associate
Lukas Schmitt, Associate
The law firm KNPZ (Dr. Kai Plath, Matthias Struck and Jan Schäfer) advised on the transaction alongside the YPOG Team on IP aspects.
About us
YPOG stands for You + Partners of Gamechangers. As a leading law and tax firm, YPOG supports founders, investors, companies and funds in Germany and internationally in bringing visionary ideas to life in the tech ecosystem and dynamic future markets.
YPOG advises on the structuring of venture capital and private equity funds, financing rounds and complex transactions, as well as on regulatory and tax matters relating to digital assets and financial innovation. As a strategic partner, YPOG develops practical solutions of the highest legal standard.
The firm combines legal and tax expertise with legal tech, digital workflows and AI-based systems to provide efficient and scalable advice.
YPOG and its professionals are regularly recognised by JUVE, Chambers and Partners, The Legal 500, Best Lawyers and Leaders League. More than 380 lawyers, tax advisers, tax specialists, one notary and business professionals work for YPOG across its offices in Berlin, Cologne, Hamburg and Munich.
Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog
